At the 33rd Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented 96-week data from the Mocha study (IMPAACT 2017), reinforcing the long-term benefits of Cabenuva for adolescents living with HIV. The analysis revealed that 94.4% of virologically suppressed participants aged 12 to 18 maintained their viral suppression after switching from daily oral pills to the every-two-month injectable regimen.
Patient preference data proved equally compelling, with 100% of participants indicating they favored long-acting injections over daily oral antiretrovirals at the 96-week mark. For many in this younger demographic, the shift represented a significant lifestyle improvement, removing the daily burden of oral medication for the first time in their lives.
As Cabenuva accounted for 55% of GSK’s HIV portfolio growth in 2025—generating £1.4 billion in sales—ViiV continues to advance its clinical pipeline to stay competitive against rivals like Gilead. The company is currently exploring the use of Cabenuva in children as young as two years old and is developing ultralong-acting combinations, such as lotivibart, aiming for dosing intervals of every four to six months.